west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "限定日剂量" 5 results
  • 精神科门诊5-羟色胺再摄取抑制剂抗抑郁药物用药状况分析

    【摘要】 目的 分析5-羟色胺再摄取抑制剂抗抑郁药物门诊治疗用药状况。 方法 抽取2010年8月23-29日四川大学华西医院精神科门诊1周的处方,采用限定日剂量分析法,分析用药频度、用药费用及合理用药情况。 结果 1周门诊量3 625例,其中焦虑抑郁性障碍1 518例(41.88%);诊断抑郁症者最多,为926例(61.0%),其次为焦虑症273例(18.0%)、焦虑状态132例(8.7%)、强迫症93例(6.1%),其余患者分别诊断为惊恐障碍、轻度抑郁症、抑郁状态及抑郁症伴焦虑等。用药频度由高到低依次为舍曲林、帕罗西汀、氟西汀、氟伏沙明和西酞普兰。日治疗消费额度由高到低依次:舍曲林、帕罗西汀、西酞普兰、氟西汀和氟伏沙明。 结论 5-羟色胺再摄取抑制剂抗抑郁药物的门诊用药符合临床合理用药规律,遵循循证医学证据用药。

    Release date:2016-09-08 09:26 Export PDF Favorites Scan
  • Analysis of Digestive Drug Use in 17 Hospitals of Chengdu Area in 2007 to 2008

    目的 了解2007年-2008年成都地区17家医院消化系统药物的使用状况。 方法 采用限定日剂量(DDD)的方法,对成都地区2007年-2008年17家医院消化系统用药的销售金额、用药频度(DDDs)等进行统计分析。 结果 2007-2008年成都地区17家医院消化系统用药总金额分别为12 527.89万元和16 446.21万元,居所有药物销售总额的第5位。在金额排序和用药频度排序中,抗溃疡药、肝病用药居于前列。 结论 消化系统药物的应用状态与同期的整体增长保持一致,相比上一年略有上涨。抗溃疡药中的质子泵抑制剂以其优异的性价比,引领着消化系统药物销售额的增长。

    Release date:2016-09-08 09:49 Export PDF Favorites Scan
  • Analysis of Cardiovascular Medisatir Usase in 17 Chengdu Local Hospitals 2007

    目的:了解2007年成都地区17家医院间心血管系统药物的使用状况。方法:采用限定日剂量(DDD)的方法,对成都地区2007年17家医院中心血管系统用药的销售金额、用药频度(DDDs)等进行统计分析。结果:2007年成都地区17家医院心血管系统用药总金额为13 753.86万元,占所有药物销售总额的9.05%。在金额排序和用药频度排序前列中,主要包括中药制剂、钙离子拮抗剂等,中药制剂类产品也销售状况良好。结论:中药制剂发挥巨大作用,依从性好、不良反应发生率低、疗效确切的药物已成为临床医师治疗心血管疾病的首选。

    Release date:2016-09-08 09:54 Export PDF Favorites Scan
  • Analysis of Biological Products and Biochemical Drugs Utilization in 17 Hospitals of Chengdu Area during 2007 to 2008

    摘要:目的:了解2007~2008年成都地区17家医院生物制品及生化药品的使用状况。方法:采用限定日剂量(DDD)的方法,对成都地区2007~2008年17家医院生物制品及生化药品的销售金额、用药频度(DDDs)等进行统计分析。结果:2007年、2008年成都地区17家医院生物制品及生化药品销售总额分别为7338万元、9786万元;分别占总销售额的4.83%、5.00%。销售金额进入总销售额排名前100位的生物制品及生化药品有:人血白蛋白、胸腺肽、丙种球蛋白、促白细胞生长素和环磷腺苷。环磷腺苷在生物制品及生化药品中的DDDs最高。结论:生物制品及生化药品的价格及供给对其临床使用有较大的限制。Abstract: Objective: To evaluate the current situation and the trend of biological products and biochemical drugs used in Chengdu city in 2007 to 2008. Methods: Consumption of biological products and biochemical drugs used in 17 hospitals of Chengdu city in 2007 to 2008 were analyzed by the way of sum DDD and DDDs ranking. Results: The total cost of the biological products and biochemical drugs used in Chengdu city in was 73.38 and 97.86 million yuan in 2007 to 2008, it accounted for 4.83% and 5.00% of the total cost. Human serum albumin, thymosin, gamma globulin, interleukin promoting growth hormone and adenosine cyclophosphate were the drugs in the first 100 cost list. The DDDs of adenosine cyclophosphate was highest among biological products and biochemical drugs. Conclusion: The cost and supply of biological products and biochemical drugs were great limitations of their clinical application.

    Release date:2016-09-08 10:12 Export PDF Favorites Scan
  • Analysis on the application of oral anticoagulants in respiratory diseases in six cities in China from 2013 to 2017

    ObjectiveTo realize the application status and development trend of oral anticoagulant drugs used in respiratory diseases in 72 hospitals in 6 cities from the year 2013 to 2017.MethodsFrom January 2013 to December 2017, we randomly selected the electronic information from 10 working days per quarter in 6 cities including Beijing, Guangzhou, Shanghai, Chengdu, Shenyang, and Zhengzhou, with 12 hospitals in each city, and summarized the information into the prescription database of the hospital prescription analysis project. Through the hospital information system, we screened out the information of outpatient prescriptions and inpatient medical records which used oral anticoagulants. The prescriptions with respiratory diseases related-diagnosis were selected as the research objects by manual screening. The application of oral anticoagulant drugs used in respiratory diseases was statistically analyzed by drug amount, prescription amount, prescribed daily dose (PDD), and defined daily dose (DDD).ResultsFrom 2013 to 2017, the number of warfarin sodium prescriptions was successively 4 769, 5 747, 7 549, 7 261, and 7 151, which had been always ranked the first in the five years, but decreased year by year since 2015. The proportion of warfarin sodium drug use amount decreased year by year from 32.52% in 2013 to 5.03% in 2017. The proportion of prescription and drug consumption sum of new oral anticoagulants increased year by year in the past five years. The PDD/DDD of warfarin sodium, dabigatran etexilate, rivaroxaban, and apixaban were 0.41, 0.73, 0.68, and 0.33, respectively. There were off lable use of new oral anticoagulants.ConclusionsWarfarin still dominates the proportion of oral anticoagulants prescribed in the 72 hospitals in the 6 cities in the five years. The clinicians have made a comprehensive judgment after fully considering the safety, effectiveness, and economy of drug use when formulating drug treatment programs.

    Release date:2019-01-23 01:20 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content